Transmission-Blocking Vaccines against Schistosomiasis Japonica
International Journal of Molecular Sciences · 30.01.2024 · 25 (3) · 1707
DOI: 10.3390/ijms25031707 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.01.2024. Verfasst von Chika P Zumuk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia. Hauptthemen laut MEDLINE: Schistosomiasis japonica, Schistosoma japonicum, Vaccines, Schistosomiasis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 234 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, NHMRC (National Health and Medical Research Council) of Australia Investigator Grant, Research Training Programme (RTP) Scholarship from the University of Queensland.
Abstract (Originalsprache)
Control of schistosomiasis japonica, endemic in Asia, including the Philippines, China, and Indonesia, is extremely challenging. Schistosoma japonicum is a highly pathogenic helminth parasite, with disease arising predominantly from an immune reaction to entrapped parasite eggs in tissues. Females of this species can generate 1000–2200 eggs per day, which is about 3- to 15-fold greater than the egg output of other schistosome species. Bovines (water buffalo and cattle) are the predominant definitive hosts and are estimated to generate up to 90% of parasite eggs released into the environment in rural endemic areas where these hosts and humans are present. Here, we highlight the necessity of developing veterinary transmission-blocking vaccines for bovines to better control the disease and review potential vaccine candidates. We also point out that the approach to producing efficacious transmission-blocking animal-based vaccines before moving on to human vaccines is crucial. This will result in effective and feasible public health outcomes in agreement with the One Health concept to achieve optimum health for people, animals, and the environment. Indeed, incorporating a veterinary-based transmission vaccine, coupled with interventions such as human mass drug administration, improved sanitation and hygiene, health education, and snail control, would be invaluable to eliminating zoonotic schistosomiasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
- Faculty of Medicine, The University of Queensland, Herston, QLD 4006, Australia.
- School of Veterinary Science, The University of Queensland, Gatton, QLD 4343, Australia.
- Centre for Childhood Nutrition Research, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia.
- Population Health Program, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
ORCID-Profile: Severine Navarro, Hong You
Förderung
- National Health and Medical Research Council
- NHMRC (National Health and Medical Research Council) of Australia Investigator Grant
- Research Training Programme (RTP) Scholarship from the University of Queensland
Zitieren
APA
Zumuk, C. P., Jones, M. K., Navarro, S., Gray, D. J., & You, H. (2024). Transmission-Blocking Vaccines against Schistosomiasis Japonica. International Journal of Molecular Sciences, 25(3), 1707. https://doi.org/10.3390/ijms25031707
Vancouver
Zumuk CP, Jones MK, Navarro S, Gray DJ, You H. Transmission-Blocking Vaccines against Schistosomiasis Japonica. International Journal of Molecular Sciences. 2024;25(3):1707. doi:10.3390/ijms25031707
BibTeX
@article{Zumuk2024,
author = {Zumuk, Chika P and Jones, Malcolm K and Navarro, Severine and Gray, Darren J and You, Hong},
title = {Transmission-Blocking Vaccines against Schistosomiasis Japonica},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {3},
pages = {1707},
doi = {10.3390/ijms25031707}
}
EUVIMED